129 related articles for article (PubMed ID: 37844759)
1. Integrated PK/PD Modeling Relates Smoothened Inhibitor Biomarkers to The Heterogeneous Intratumor Disposition of Cetuximab in Pancreatic Cancer Tumor Models.
Wang J; Chen T; Ruszaj DM; Mager DE; Straubinger RM
J Pharm Sci; 2024 Jan; 113(1):72-84. PubMed ID: 37844759
[TBL] [Abstract][Full Text] [Related]
2. Tumor Priming by SMO Inhibition Enhances Antibody Delivery and Efficacy in a Pancreatic Ductal Adenocarcinoma Model.
Wang J; Chan DKW; Sen A; Ma WW; Straubinger RM
Mol Cancer Ther; 2019 Nov; 18(11):2074-2084. PubMed ID: 31363010
[TBL] [Abstract][Full Text] [Related]
3. Dual-Hit Strategy for Therapeutic Targeting of Pancreatic Cancer in Patient-Derived Xenograft Tumors.
Roy Chaudhuri T; Lin Q; Stachowiak EK; Rosario SR; Spernyak JA; Ma WW; Stachowiak MK; Greene MK; Quinn GP; McDade SS; Clynes M; Scott CJ; Straubinger RM
Clin Cancer Res; 2024 Apr; 30(7):1367-1381. PubMed ID: 38270582
[TBL] [Abstract][Full Text] [Related]
4. Tumor-Priming Smoothened Inhibitor Enhances Deposition and Efficacy of Cytotoxic Nanoparticles in a Pancreatic Cancer Model.
Roy Chaudhuri T; Straubinger NL; Pitoniak RF; Hylander BL; Repasky EA; Ma WW; Straubinger RM
Mol Cancer Ther; 2016 Jan; 15(1):84-93. PubMed ID: 26516158
[TBL] [Abstract][Full Text] [Related]
5. Impacting Pancreatic Cancer Therapy in Heterotypic
Obaid G; Bano S; Mallidi S; Broekgaarden M; Kuriakose J; Silber Z; Bulin AL; Wang Y; Mai Z; Jin W; Simeone D; Hasan T
Nano Lett; 2019 Nov; 19(11):7573-7587. PubMed ID: 31518145
[TBL] [Abstract][Full Text] [Related]
6. Tumor-Specific Delivery of 5-Fluorouracil-Incorporated Epidermal Growth Factor Receptor-Targeted Aptamers as an Efficient Treatment in Pancreatic Ductal Adenocarcinoma Models.
Mahajan UM; Li Q; Alnatsha A; Maas J; Orth M; Maier SH; Peterhansl J; Regel I; Sendler M; Wagh PR; Mishra N; Xue Y; Allawadhi P; Beyer G; Kühn JP; Marshall T; Appel B; Lämmerhirt F; Belka C; Müller S; Weiss FU; Lauber K; Lerch MM; Mayerle J
Gastroenterology; 2021 Sep; 161(3):996-1010.e1. PubMed ID: 34097885
[TBL] [Abstract][Full Text] [Related]
7. Photoimmunotherapy Retains Its Anti-Tumor Efficacy with Increasing Stromal Content in Heterotypic Pancreatic Cancer Spheroids.
Saad MA; Zhung W; Stanley ME; Formica S; Grimaldo-Garcia S; Obaid G; Hasan T
Mol Pharm; 2022 Jul; 19(7):2549-2563. PubMed ID: 35583476
[TBL] [Abstract][Full Text] [Related]
8. Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer.
Lindberg JM; Newhook TE; Adair SJ; Walters DM; Kim AJ; Stelow EB; Parsons JT; Bauer TW
Neoplasia; 2014 Jul; 16(7):562-71. PubMed ID: 25117978
[TBL] [Abstract][Full Text] [Related]
9. Mesothelin and TGF-α predict pancreatic cancer cell sensitivity to EGFR inhibitors and effective combination treatment with trametinib.
Poteet E; Liu D; Liang Z; Van Buren G; Chen C; Yao Q
PLoS One; 2019; 14(3):e0213294. PubMed ID: 30921351
[TBL] [Abstract][Full Text] [Related]
10. Co-targeting of EGF receptor and neuropilin-1 overcomes cetuximab resistance in pancreatic ductal adenocarcinoma with integrin β1-driven Src-Akt bypass signaling.
Kim YJ; Jung K; Baek DS; Hong SS; Kim YS
Oncogene; 2017 May; 36(18):2543-2552. PubMed ID: 27797376
[TBL] [Abstract][Full Text] [Related]
11. The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells.
Momeny M; Esmaeili F; Hamzehlou S; Yousefi H; Javadikooshesh S; Vahdatirad V; Alishahi Z; Mousavipak SH; Bashash D; Dehpour AR; Tavangar SM; Tavakkoly-Bazzaz J; Haddad P; Kordbacheh F; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Cell Oncol (Dordr); 2019 Aug; 42(4):491-504. PubMed ID: 31025257
[TBL] [Abstract][Full Text] [Related]
12. Dynamic Contrast-Enhanced Magnetic Resonance Imaging for the Prediction of Monoclonal Antibody Tumor Disposition.
Bordeau BM; Polli JR; Schweser F; Grimm HP; Richter WF; Balthasar JP
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054865
[TBL] [Abstract][Full Text] [Related]
13. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
14. Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma.
Zhao X; Fan W; Xu Z; Chen H; He Y; Yang G; Yang G; Hu H; Tang S; Wang P; Zhang Z; Xu P; Yu M
Oncotarget; 2016 Dec; 7(49):81110-81122. PubMed ID: 27835602
[TBL] [Abstract][Full Text] [Related]
15. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
[TBL] [Abstract][Full Text] [Related]
16. Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer.
Dosch AR; Dai X; Reyzer ML; Mehra S; Srinivasan S; Willobee BA; Kwon D; Kashikar N; Caprioli R; Merchant NB; Nagathihalli NS
Mol Cancer Res; 2020 Apr; 18(4):623-631. PubMed ID: 31949002
[TBL] [Abstract][Full Text] [Related]
17. GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation.
Nolan-Stevaux O; Lau J; Truitt ML; Chu GC; Hebrok M; Fernández-Zapico ME; Hanahan D
Genes Dev; 2009 Jan; 23(1):24-36. PubMed ID: 19136624
[TBL] [Abstract][Full Text] [Related]
18. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma.
Rhim AD; Oberstein PE; Thomas DH; Mirek ET; Palermo CF; Sastra SA; Dekleva EN; Saunders T; Becerra CP; Tattersall IW; Westphalen CB; Kitajewski J; Fernandez-Barrena MG; Fernandez-Zapico ME; Iacobuzio-Donahue C; Olive KP; Stanger BZ
Cancer Cell; 2014 Jun; 25(6):735-47. PubMed ID: 24856585
[TBL] [Abstract][Full Text] [Related]
19. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K
Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027
[TBL] [Abstract][Full Text] [Related]
20. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.
Indolfi L; Ligorio M; Ting DT; Xega K; Tzafriri AR; Bersani F; Aceto N; Thapar V; Fuchs BC; Deshpande V; Baker AB; Ferrone CR; Haber DA; Langer R; Clark JW; Edelman ER
Biomaterials; 2016 Jul; 93():71-82. PubMed ID: 27082874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]